Advertisement

Clinical Rheumatology

, Volume 35, Issue 4, pp 919–925 | Cite as

The investigation of killer cell immunoglobulin-like receptor genotyping in patients with systemic lupus erytematosus and systemic sclerosis

  • Jülide Duymaz TozkırEmail author
  • Hilmi Tozkır
  • Hakan Gürkan
  • Salim Dönmez
  • Damla Eker
  • Gülsüm Emel Pamuk
  • Ömer Nuri Pamuk
Original Article

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by the production of autoantibodies and the involvement of multiple organ systems. Systemic sclerosis (SSc) is another autoimmune disease that causes fibrosis. We will aim to analyse the role of killer cell immunoglobulin-like receptor (KIR) genotypes and their existence with the respective HLA ligands in patients with SLE and SSc. Forty-five SLE, 25 SSc and 40 healthy controls were included. We examined the presence/absence of KIR2DL1, 2DL2, 2DL3, 2DL4, 2DL5A, 2DL5B, 2DS1, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1, 2DP1, 3DP1 and their known HLA ligands. In the SLE group, the KIR2DL5, KIR2DL5B and KIR2DS3 genes were significantly more frequent, and KIR2DL3 gene was significantly less than in controls (p values <0.05). In SSc patients, the KIR2DS3 gene was more frequent than in controls (p = 0.032). The KIR2DL3 gene was detected more frequently in controls while KIR2DS3 gene was more frequent in the patient group when SLE and SSc patients were combined (p values < 0.05). The KIR2DS2/HLA-C and KIR2DS2/HLA-C combinations were significantly more in both SLE and SSc groups than in controls. The KIR2DL2 and KIR2DL5B genes were protective from neurologic involvement in SLE patients (p values <0.05). The variations of some KIR genes such as KIR2DL5, KIR2DL5B, KIR2DS3 and KIR2DL3 may have a role in the pathogenesis of SLE and SSc. Also, the presence of KIR2DL2 and KIR2DL5B may cause major organ involvement, like neurologic involvement, in SLE.

Keywords

Genetic Killer cell immunoglobulin-like receptors (KIRs) Systemic lupus erythematosus (SLE) Systemic sclerosis (SSc) 

Notes

Acknowledgments

This study was supported by grants from The Scientific And Technological Research Council Of Turkey (TUBITAK) 3501—Career Development Program (Project number: 111S153). The authors acknowledge Dr. Canpolat Polat for his translational and linguistic assistance.

Compliance with ethical standards

Disclosures

None.

References

  1. 1.
    Relle M, Weinmann-Menke J, Scorletti E, Cavagna L, Schwarting A (2015) Genetics and novel aspects of therapies in systemic lupus erythematosus. Autoimmun Rev. doi: 10.1016/j.autrev.2015.07.003 PubMedGoogle Scholar
  2. 2.
    Romano E, Manetti M, Guiducci S, Ceccarelli C, Allanore Y, Matucci-Cerinic M (2011) The genetics of systemic sclerosis: an update. Clin Exp Rheumatol 29(2 Suppl 65):S75–86PubMedGoogle Scholar
  3. 3.
    Vivier E, Anfossi N (2004) Inhibitory NK-Cell Receptors on T Cells: Witness of the Past. Actors of the Future. Nat Rev Immunol 4:190–198CrossRefPubMedGoogle Scholar
  4. 4.
    Parham P (2005) MHC class I molecules and KIRs in human history. Health and survival. Nat Rev Immunol 5:201–214CrossRefPubMedGoogle Scholar
  5. 5.
    Vilches C, Parham P (2002) KIR: diverse rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 20:217–51CrossRefPubMedGoogle Scholar
  6. 6.
    Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH (2002) Structure and function of NK cell receptors: multiple molecular solutions to self. Nonself discrimination. Annu Rev Immunol 20:853–885CrossRefPubMedGoogle Scholar
  7. 7.
    Masi AT, Rodnan GP, Medsger TA Jr et al (1980) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–90CrossRefGoogle Scholar
  8. 8.
    Momot T, Koch S, Hunzelmann N, Krieg T, Ulbricht K, Schmidt RE, Witte T (2004) Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 50(5):1561–1565CrossRefPubMedGoogle Scholar
  9. 9.
    Salim PH, Jobim M, Bredemeier M, Chies JAB, Schlottfeldt J, Brenol JCT, Jobim LF, Xavier RM (2010) Killer cell immunoglobulin like receptor (KIR) genes in systemic sclerosis. Clin Exp Immunol 160:325–330CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Pellett F, Siannis F, Vukin I, Lee P, Urowitz MB, Gladman DD (2007) KIRs and autoimmune disease: studies lupus erythematosus and scleroderma. Tissue Antigens 69(Suppl 1):106–108CrossRefPubMedGoogle Scholar
  11. 11.
    Pedroza LS, Sauma MF, Vasconcelos JM, Takeshita LY, Ribeiro-Rodrigues EM, Sastre D, Barbosa CM, Chies JA, Veit TD, Lima CP, Oliveira LF, Henderson BL, Castro AP, Maia MH, Barbosa FB, Santos SE, Guerreiro JF, Sena L, Santos EJ (2010) Systemic lupus erythematosus: association with KIR and SLC11A1 polymorphisms, ethnic predisposition and influence in clinical manifestations at onset revealed by ancestry genetic markers in an urban Brazilian population. Lupus 20(3):265–73CrossRefGoogle Scholar
  12. 12.
    Toloza SMA, Pellett FJ, Chandran V, Ibanez D, Urowitz MB, Gladman DD (2008) Association of killer cell immunoglobulin-like receptor genotypes with vascular arterial events and anticardiolipin antibodies in patient with lupus. Lupus 17:793–798CrossRefPubMedGoogle Scholar
  13. 13.
    Spaggiari GM, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F, Zocchi MR, Poggi A (2002) Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood 100(12):4098–107CrossRefPubMedGoogle Scholar
  14. 14.
    Saulquin X, Gastinel LN, Vivier E (2003) Crystal structure of the human natural killer cell activating receptor KIR2DS2 (CD158j). J Exp Med 197(7):933–8CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kim S, Sunwoo JB, Yang L, Choi T, Song YJ, French AR, Vlahiotis A, Piccirillo JF, Cella M, Colonna M, Mohanakumar T, Hsu KC, Dupont B, Yokoyama WM (2008) HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A 105(8):3053–8CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Cauli A, Shaw J, Giles J, Hatano H, Rysnik O, Payeli S, McHugh K, Dessole G, Porru G, Desogus E, Fiedler S, Hölper S, Carette A, Blanco-Gelaz MA, Vacca A, Piga M, Ibba V, Garau P, La Nasa G, López-Larrea C, Mathieu A, Renner C, Bowness P, Kollnberger S (2013) The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09. Rheumatology 52(11):1952–62CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Liu J, Xiao Z, Ko HL, Shen M, Ren EC (2014) Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11. Proc Natl Acad Sci U S A 111(7):2662–7CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hou Y, Zhang C, Xu D, Sun H (2015) Association of KIR and HLA-Cw genes combinations with systemic lupus erythematosus. Clin Exp Immunol. doi: 10.1111/cei.12582 PubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2016

Authors and Affiliations

  • Jülide Duymaz Tozkır
    • 1
    Email author
  • Hilmi Tozkır
    • 2
  • Hakan Gürkan
    • 2
  • Salim Dönmez
    • 3
  • Damla Eker
    • 2
  • Gülsüm Emel Pamuk
    • 4
  • Ömer Nuri Pamuk
    • 3
  1. 1.Health Services Vocational CollegeTrakya UniversityEdirneTurkey
  2. 2.Medical Faculty, Division of Medical GeneticsTrakya UniversityEdirneTurkey
  3. 3.Medical Faculty, Division of RheumatologyTrakya UniversityEdirneTurkey
  4. 4.Medical Faculty, Division of HaematologyTrakya UniversityEdirneTurkey

Personalised recommendations